Health Costs

New and noteworthy

The MIDTERMS

“...the search for a single top issue through polling questions — whether it’s health costs, or gas prices, or the cost of food — is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, ‘cost of living.’” — Drew Altman, KFF Founding President and CEO

Are Health Care Costs THE Top Issue for Voters?

In a new column, Dr. Drew Altman, Founding President and CEO, analyzes the polling on health costs as a voting issue and concludes that there is no one top voting issue. He writes: “I have come to the conclusion that the search for a single top issue through polling questions—whether it’s health costs, or gas prices, or the cost of food—is artificial. People worry about and experience these costs together. There is no top issue, unless that issue is the catchall, “cost of living.”

Health System Tracker

Stay informed.

Stay informed.

Filter

1,221 - 1,230 of 1,604 Results

  • What We Know About Provider Consolidation

    Issue Brief

    This brief reviews what we know about the impact of provider consolidation on health care prices and quality and finds that consolidation leads to higher prices with no compelling evidence of commensurate quality improvements.

  • Cost-Sharing Waivers and Premium Relief by Private Plans in Response to COVID-19 (Nov. 2020 Update)

    Issue Brief

    An updated issue brief estimates the number of enrollees in individual and fully-insured group market plans that have waived cost-sharing – out-of-pocket costs including coinsurance, copayments, and deductibles – for COVID-19 treatment. The analysis also estimates the number of enrollees whose insurer is offering various forms of premium payment relief. The updated analysis finds that, as of November 2020, about half (49%) of fully-insured plan enrollees have coverage that waives cost-sharing for COVID-19 treatment through…

  • Why Deductibles Would Rise Under the GOP Health Care Plan

    From Drew Altman

    This inaugural Drew Altman column for Axios examines how the GOP House bill would impact deductibles for people who buy insurance in the non-group market. A KFF analysis for the column shows deductibles in a typical non-group plan would be about $1550 higher under the American Health Care Act compared to the Affordable Care Act.

  • Poll: Public Views the ACA More Favorably Than Congress’ Plan to Replace It, Though Republicans Favor the Replacement

    News Release

    Public Grows More Pessimistic About How Repeal Will Affect Them Personally Most (55%) of the public holds an unfavorable view of the Congressional plan that would repeal and replace the Affordable Care Act, and the same share (55%) want the Senate either to make major changes to the House-passed bill or not pass it all, finds the latest Kaiser Health Tracking Poll. Three in 10 (31%) of the public hold favorable views of the American…

  • Don’t Overhype the New Health Care Venture

    From Drew Altman

    In an Axios column, Drew Altman dissects the many dimensions of the health cost problem and discusses why the Bezos-Buffett-Dimon initiative is unlikely to have much impact on the larger health cost problems the public and policymakers care about most.

  • How have healthcare prices grown in the U.S. over time?

    Feature

    This chart collection explores price increases in private insurance for common services over time and finds significant geographic variation in prices. For example, the average price of a full knee replacement for those in large employer plans increased from $19,595 in 2003 to $34,063 in 2016, growth of 74% compared to a 28% increase in general inflation. The average price of a knee replacement in New York City is more than twice the price of…

  • New KFF Resource Tracks Proposed 2019 Marketplace Premiums By State

    News Release

    The Kaiser Family Foundation today launched a tracker to monitor preliminary 2019 premiums in the Affordable Care Act’s marketplaces as insurers file rate information with state regulators. Beginning with data from eight states (Maine, Maryland, New York, Oregon, Rhode Island, Vermont, Virginia and Washington) plus the District of Columbia, the tracker shows preliminary premium information in nine major cities for the lowest-cost bronze plan and “benchmark” silver plan, which is used to determine the size of the…

  • FAQs on Prescription Drug Importation

    Issue Brief

    These FAQs address questions related to prescription drug importation, including the current status of importation proposals, details of Florida’s importation program recently authorized by the FDA, and concerns and challenges with this approach.